Accession Number: | 0001209191-21-012105 |
Date: | 2021-02-16 |
Issuer: | AMICUS THERAPEUTICS, INC. (FOLD) |
Original Submission Date: |
CROWLEY JOHN F
C/O AMICUS THERAPEUTICS, INC.
3675 MARKET STREET
PHILADELPHIA, PA 19104
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-02-16 | M | 22,000 | a | $6.45 | 873,888 | direct | ||
COMMON STOCK | 2021-02-16 | S | 22,000 | d | $12.26 | 851,888 | direct | ||
COMMON STOCK | 2021-02-16 | 0 | $0.00 | 64,895 | indirect |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTIONS (RIGHT TO BUY) | 6.45 | 2021-02-16 | deemed execution date | M | 22,000 (d) | 2022-02-15 | common stock 22,000 | $6.45 | 64,557 | direct |
ID | footnote |
---|---|
f1 | the sales reported in this form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person. |
f2 | this price is the weighted average price for the transactions reported on this line. the prices for the transactions reported on this line range from $12.01 to $12.76 inclusive. the reporting person undertakes to provide, upon request, by the staff of the securities and exchange commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
f3 | all of these options were fully vested and exercisable as of february 16, 2021. |